|Day Low/High||89.06 / 90.25|
|52 Wk Low/High||75.90 / 143.45|
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it has signed a definitive asset purchase agreement to acquire CTP-656 from Concert Pharmaceuticals (Nasdaq: CNCE).
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Cowen Healthcare Conference on Monday, March 6 th at 2:00 p.
Jana Partners are placing three members on Tiffany's board.
Biopharma's reticence suggests that fear of Trump's tweets and threats to limit drug pricing (and cut into profits) has stopped biotech companies from standing up for what's right.
Neurocrine Biosciences, Aralez Pharmaceuticals and Qiagen were among the biotech stock movers in premarket trading on Friday.
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the full-year and quarter-ended December 31, 2016.
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it has entered into a licensing agreement with Merck KGaA, Darmstadt, Germany for the worldwide development and commercialization of four promising...
The $5.2 billion takeout of Ariad Pharma was the biggest news from the closely followed healthcare conference.
Vertex Pharmaceuticals will be weighing future acquisitions and partnerships to broaden is focus beyond cystic fibrosis.
Vertex Pharmaceuticals is often mentioned as a takeover target, but the company is evaluating potential acquisitions and partnerships of its own to diversify beyond cystic fibrosis.
Vertex Pharmaceuticals provided new financial guidance for 2017 on Sunday.
Results from two studies of next-generation "correctors" for cystic fibrosis, expected in the second half of 2017, will be stock-moving events.
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today provided an update on its business performance, including preliminary financial results for 2016 and a financial outlook for 2017, and an update on its ongoing...
Next week the J.P. Morgan Healthcare Conference becomes the hottest spot in biotech and pharma.
The biggest annual event for biotech and pharma investors starts Monday with the kickoff of the J.P. Morgan Healthcare Conference in San Francisco.
Every January at 'JPM,' investors take the pulse of the biotech industry for the coming year.
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the 35 th Annual J.
Jim Cramer outlines what he thinks this market needs to keep the Trump rally rolling in 2017.
Adam Feuerstein compiles a list of questions, thoughts, declarations, catalysts and observations about biotech stocks to help investors prepare for the year ahead.
Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) today announced it has reached a pricing and reimbursement agreement for ORKAMBI ® (lumacaftor/ivacaftor) with the German Federal Association of the Statutory...
The most recent short interest data has been released for the 11/30/2016 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.
Broadcom released better-than-expected 2016 fourth-quarter results, and its stock on Friday is giving a picture of where the rally could 'broaden to,' says Jim Cramer.
Buy signals have not lasted more than two months, so far.
Here are Tuesday's top research calls, including an upgrade for Pfizer, and downgrades for Goldman Sachs, Johnson & Johnson, Delphi and Darden Restaurants.
For as much as we love and respect you, Gilead, the current situation is unacceptable. The once great and mighty biotech Gilead cannot trade at a 6x forward earnings multiple!
Investors have convinced themselves that President Donald Trump is going to make drug stocks great again. Will it last?